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Key Points




Pyruvate kinase deﬁciency (PKD) is the most common cause of congenital nonspherocytic
hemolytic anemia. Although recognition of the disease spectrum has recently expanded,

The impact of PKD on
HRQoL and fatigue is
described in 254
children and adults
using 6 validated
instruments.

data describing its impact on health-related quality of life (HRQoL) are limited. In this

Severe anemia, regular
transfusion, iron
chelation, and
nonmissense mutations are associated
with worse patientreported outcomes.

Illness Therapy-Fatigue). Signiﬁcant variability in HRQoL and fatigue was reported for

prospective international cohort of 254 patients (131 adults and 123 children) with PKD, we
used validated measures to assess the impact of disease on HRQoL (EuroQol 5-Dimension
Questionnaire, Pediatric Quality of Life Inventory Generic Core Scale version 4.0, and
Functional Assessment of Cancer Therapy-Anemia) and fatigue (Patient Reported Outcomes
Measurement Information System Fatigue and Pediatric Functional Assessment of Chronic
adults and children, although individual scores were stable over a 2-year interval. Although
adults who were regularly transfused reported worse HRQoL and fatigue compared with
those who were not (EuroQol-visual analog scale, 58 vs 80; P 5 .01), this difference was not
seen in children. Regularly transfused adults reported lower physical, emotional, and
functional well-being and more anemia symptoms. HRQoL and fatigue signiﬁcantly differed
in children by genotype, with the worst scores in those with 2 severe PKLR mutations; this
difference was not seen in adults. However, iron chelation was associated with signiﬁcantly
worse HRQoL scores in children and adults. Pulmonary hypertension was also associated
with signiﬁcantly worse HRQoL. Additionally, 59% of adults and 35% of children reported
that their jaundice upset them, identifying this as an important symptom for consideration.
Although current treatments for PKD are limited to supportive care, new therapies are in
clinical trials. Understanding the impact of PKD on HRQoL is important to assess the utility
of these treatments. This trial was registered at www.clinicaltrials.gov as #NCT02053480.

Introduction
Pyruvate kinase deﬁciency (PKD) is an autosomal recessive hereditary hemolytic anemia resulting from
mutations in the PKLR gene. Although it is the most common cause of chronic hereditary nonspherocytic
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Although data from the international Pyruvate Kinase Deﬁciency Natural History Study (PKD NHS)5 and other cohorts7-9 have been important in deﬁning the disease spectrum, few objective or quantitative
published data have described the impact of PKD on health-related
quality of life (HRQoL) or fatigue. A qualitative interview study of 21
adults with PKD described a negative impact of the disease on
appearance, emotional and cognitive states, sleep, work and/or
school, and the ability to perform physical, social, and leisure activities.10 Studies published in other hereditary hemolytic anemias,
such as sickle cell disease11 and thalassemia,12 demonstrated the
importance of deﬁning the impact of chronic hemolytic anemia on
patient-reported outcomes, underscoring its signiﬁcance as an outcome measure in the evaluation of treatments. Although treatments
for PKD are limited to red blood cell transfusions, splenectomy, and
the rare hematopoietic stem cell transplant, oral pyruvate kinase activators13 and gene therapy14 are in clinical trials. Understanding the
impact of PKD on HRQoL and fatigue is critical to fully characterize
the value and utility of these treatments. Therefore, this study aimed
to characterize the disease impact on HRQoL and fatigue in an international population of children and adults with PKD.

Methods
Patient population
The PKD NHS (#NCT02053480) was opened at 30 centers in the
United States (n 5 19), Canada (n 5 3), Italy (n 5 1), Czech Republic
(n 5 1), Germany (n 5 5), and The Netherlands (n 5 1) (supplemental
Table 1). The study protocol was in accordance with the Declaration
of Helsinki and was approved by the Institutional Review Board and/or
Ethics Committee at each site, and all patients and/or their legal
guardians gave informed consent. Patients were able to participate
from afar by signed medical releases or were primarily followed at a
center approved to conduct the study. Patients were eligible to be
included in the registry study if they had a genetically conﬁrmed diagnosis of PKD with 2 identiﬁed PKLR mutations. At the time of enrollment, patients’ medical records were reviewed retrospectively, and
patients were followed prospectively for 2 years. Data collected
from the medical record included medical history, physical examination, and laboratory and radiologic studies. Medical history missing
from the medical records was obtained by patient recall, if known.
HRQoL was measured at 3 time points: at enrollment and at the 1and 2-year follow-up in children (,18 years) and adults ($18 years).
22 MARCH 2022 • VOLUME 6, NUMBER 6

Patient-reported outcome measures
Adult measures. MEASUREMENT OF HRQoL. The EuroQol
5-Dimension Questionnaire (EQ-5D-5L) was used in adults (supplemental Table 2). The EQ-5D is a generic HRQoL instrument that
includes 2 primary components: a descriptive system used to generate a EuroQol health index score and the EuroQol-visual analog scale
(EQ-VAS), in which respondents mark health status on a vertical scale
with end points of 0 (worst health) and 100 (best health). EQ-5D scoring has been validated across multiple chronic diseases and in different countries. The Functional Assessment of Cancer Therapy-Anemia
(FACT-An), a validated survey that measures general HRQoL concerns (physical, social, emotional, and functional well-being), as well
as items speciﬁcally related to anemia and fatigue, was used to measure adult HRQoL. Scores range from 0 to 188; a higher score indicates a higher level of HRQoL (supplemental Table 2).
MEASUREMENT OF FATIGUE. The Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short
Form was used to measure fatigue in adults (adult self-report shortform 7a [SF7a]). PROMIS raw scores are converted to T-scores; a
standardized score has a mean of 50 and a standard deviation (SD)
of 10. Higher scores indicate greater fatigue. English-speaking adults
were asked an additional question for symptom assessment speciﬁc
to PKD (“I get upset about my jaundice [yellow eyes/skin]”), which
used a scale from 0 (not at all) to 5 (very much).
Pediatric measures.
MEASUREMENT OF HRQoL. The
Pediatric Quality of Life Inventory Generic Core Scale version 4.0
(PedsQL), a validated tool that measures physical, emotional, social,
and school functioning, was completed for children and adolescents
(supplemental Table 2). Parent proxy forms were completed for children aged 2 to 17 years, whereas patient self-report forms were completed for children aged 5 to 17 years. PedsQL scores have a range of
0 (worst) to 100 (best).
MEASUREMENT OF FATIGUE. The Pediatric Functional
Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F)
was used to measure fatigue in children aged 8 to 17 years. Scores
can range from 0 to 52; a lower score indicates a higher level of
fatigue. The PROMIS Fatigue Short Form 10a (SF-10a) was
used to measure fatigue in children aged 8 to 17 years (child
self-report 10a) and parent proxy forms (parent proxy 10a) were
used for children aged 5 to 17 years. Analysis of the child and parent proxy short forms is the same as for the adult forms; higher
scores indicate greater fatigue. English-speaking children were
asked an additional question for symptom assessment speciﬁc to
PKD (“I get upset about my jaundice [yellow eyes/skin]”), which
used a scale from 0 (none of the time) to 5 (all of the time).

Deﬁnitions and statistical analysis
Patient demographics, transfusion status, comorbid diagnoses, and
other disease characteristics were described using frequencies, proportions, medians, means, and ranges. Patients were considered regularly transfused if they had received $6 red blood cell transfusions in
the prior year. Iron overload was deﬁned as elevated ferritin ($1000
ng/mL) or by the use of iron chelation at any point. Because the Amish
population represented a large and similarly managed subset of the
cohort, analyses were performed for the entire cohort and for the
Amish population separately. Tests of association were performed
using the Fisher’s exact test for categorical data and the Wilcoxon
rank-sum test or the Kruskal-Wallis test for continuous data. Sample
QUALITY OF LIFE AND FATIGUE IN PKD
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hemolytic anemia, its precise prevalence remains unclear, with estimates ranging between 1:20 000 and 1:300 000 in white populations1,2 and a higher prevalence in malaria-endemic areas. Pyruvate
kinase is the rate-limiting step in erythrocyte adenosine triphosphate
production; the shortage of adenosine triphosphate resulting from
its deﬁciency results in a diminished capacity to maintain the erythrocyte membrane and decreased erythrocyte deformability.3 This leads
to chronic hemolytic anemia that is due to decreased erythrocyte lifespan and premature splenic erythrocyte destruction. Hemolysis in
PKD ranges from mild and asymptomatic to a severe transfusiondependent anemia from birth.4 The sequelae include typical
symptoms of anemia (fatigue, reduced exercise tolerance, reduced
concentration), iron overload and its complications, extramedullary
hematopoiesis, bone disease, endocrinopathies, and venous thromboembolism, among other complications.5,6

sizes are presented for those with known data available for each variable. Spearman correlations are reported. Data were collected using
Inform and analyzed with SAS v9.4 (Cary, NC). Surveys were unavailable in speciﬁc languages, which led to more missing data for certain
measures (supplemental Table 2). The EQ-5D summary health index
score was computed using country-speciﬁc value sets. P values are
2-sided, and those ,.05 were considered statistically signiﬁcant.

Results
PKD NHS demographics

Report of overall HRQoL in adults with PKD
EQ-5D-5L. The EQ-5D Visual Analog Scale was completed by 120
of the 131 adults at enrollment, by 98 at the 1-year follow-up, and by
88 patients at the 2-year follow-up. The median EQ-VAS score was
80, with signiﬁcant variability in the range of scores reported (20100). The median EuroQol health index score was 0.88 (range,
0.43-1). The median EQ-VAS and health index scores were
unchanged at 1 and 2 years of follow-up.

FACT-An subscales. Within the FACT-An, differences were
noted in speciﬁc subscales across clinical characteristics. Lower
scores in the social well-being subscale were reported by patients
aged $40 years vs ,40 years (22 vs 26; P 5 .0006) and those
who had not been splenectomized vs those postsplenectomy (21
vs 25; P 5 .004). Additionally, lower scores in the anemia subscale
were reported for females vs males (58 vs 67; P 5 .001). Regularly
transfused adults reported signiﬁcantly lower physical well-being
(P 5 .002), emotional well-being (P 5 .004), and functional wellbeing (P 5 .0007), as well as increased anemia symptoms (P 5
.0002). Those with a history of iron overload by chelation requirement
also reported lower physical well-being (P 5 .0001), emotional wellbeing (P 5 .001), and functional well-being (P 5 .0007), as well as
increased anemia symptoms (P 5 .02). In addition, pulmonary hypertension was associated with signiﬁcantly lower physical well-being
(P 5 .0004) and functional well-being (P 5 .005), as well as
increased anemia symptoms (P 5 .0008).

Report of fatigue in adults with PKD

At the time of enrollment, patients aged $40 years reported signiﬁcantly lower EQ-VAS scores compared with adults aged 18 to 39
years (80 vs 85; P 5 .02). Scores were lower in women vs men
(80 vs 85; P 5 .03), in non-Amish vs Amish patients (80 vs 85;
P 5 .04), regularly transfused vs not regularly transfused patients
(58 vs 80; P 5 .01), in patients with iron overload vs no iron overload
by chelation requirement (75 vs 84; P 5 .02), and in patients with vs
without pulmonary hypertension (40 vs 80; P 5 .03). When the Amish
population was excluded from the analysis, there were no longer signiﬁcant differences by age or history of iron overload by chelation
requirement. EQ-VAS scores did not differ based on splenectomy status (P 5 .67), hemoglobin level (,8 g/dL vs .8 g/dL; P 5 .97), bilirubin level (total bilirubin . 4 mg/dL vs ,4 mg/dL, P 5 .97), number
of lifetime transfusions (P 5 .20), iron overload by ferritin (P 5 .12), or
history of extramedullary hematopoiesis (P 5 .31). EQ-VAS scores
also did not differ by genotype category: missense/missense (median,
75), missense/nonmissense (median, 83), and nonmissense/nonmissense (median, 80; P 5 .28).

PROMIS SF-7a. The PROMIS SF-7a was completed by 60 adults
at enrollment and by 47 and 36 adults at 1 and 2 years of follow-up,
respectively. The lower number of respondents for this inventory
reﬂects the lack of validated translated forms for some of the participating countries. The median PROMIS SF-7a score was 52.3 (range:
29.4-80.3), and this median was replicated at years 1 and 2.

FACT-An. The FACT-An was completed by 126 adults at enrollment, by 98 patients at the 1-year follow-up, and by 88 patients at the
2-year follow-up. The median FACT-An score was 155.6, with high
variability between individual patient scores (range, 33.3-181). The
median FACT-An score was similar at 1 and 2 years of follow-up.

Other report of symptoms of anemia. English-speaking
adults were asked an additional question for symptom assessment
speciﬁc to PKD (Table 3). Of the 68 adults who completed the questionnaire, 59% (40/68) reported that their jaundice upset them, and
16% (11/68) reported that they felt quite a bit or very much upset.

At enrollment, HRQoL assessed by FACT-An did not vary by age. Signiﬁcantly lower HRQoL was reported by women vs men (median, 143
vs 159; P 5 .008), non-Amish vs Amish patients (151 vs 163; P 5
.04), regularly vs not regularly transfused patients (113 vs 157; P 5
.0003), patients with iron overload vs no iron overload by chelation
1846
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In adults, fatigue levels using PROMIS SF-7a did not vary by age or by
Amish/non-Amish status. Signiﬁcantly greater levels of fatigue were
reported by women vs men (57 vs 51; P 5 .004), regularly vs not regularly transfused patients (68 vs 52; P 5 .03), and patients with vs
without pulmonary hypertension (65 vs 52; P 5 .04). Report of fatigue
did not differ based on splenectomy status (P 5 .59), hemoglobin
level (,8 g/dL vs .8 g/dL; P 5 .93), bilirubin level (total bilirubin
. 4 mg/dL vs ,4 mg/dL; P 5 .28), number of lifetime transfusions
(P 5 .37), history of extramedullary hematopoiesis (P 5 .43), iron overload by ferritin (P 5 .12), or iron overload by chelation (P 5 .20).
Reports of fatigue also did not differ by PKLR genotype category
(P 5 .79).

Report of overall HRQoL in children with PKD
The PedsQL 4.0 survey was completed by 61 of the 124 children at
enrollment, by 45 children at the 1-year follow-up, and by 48 children
at the 2-year follow-up. The parent proxy was completed by 86 of 124
22 MARCH 2022 • VOLUME 6, NUMBER 6
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Patients with PKD were enrolled from June of 2014 through April of
2017 at 30 centers in 6 countries. Data are reported for 254 eligible
participants (131 adults and 123 adolescents and children). There
were 55 patients (21.7%) who identiﬁed as part of the Amish community. Baseline demographic information is presented in Table 1. A
comprehensive characterization of the complications and laboratory
abnormalities associated with PKD in this population is described in
a separate publication.5 Completed HRQoL surveys varied by age
and measure (Table 2; supplemental Table 2).

requirement (146 vs 157; P 5 .006), and patients with vs without pulmonary hypertension (99 vs 157; P 5 .002). HRQoL did not differ
based on splenectomy status (P 5 .95), hemoglobin level (,8 g/dL
vs . 8 g/dL; P 5 .97), bilirubin level (total bilirubin . 4 mg/dL vs
,4 mg/dL; P 5 .4), number of lifetime transfusions (P 5 .18), or
iron overload by ferritin (P 5 .12). There were no signiﬁcant differences based on PKLR genotype (P 5 .63). Differences, or the lack
thereof, in FACT-An scores in certain subgroups are shown in
Figure 1.

Table 1. Demographic characteristics of the PKD cohort
All (N = 254)
Characteristics

n*

Male sex

% or median (range)

124

48.9

19.0 (0.1-69.9)

Age at enrollment, y
254
123

6.4 (0.1-17.7)

$18 y old

131

36.2 (18.0-69.9)

White race

235

92.5

Hispanic ethnicity

18

7.1

Amish

55

21.7

Splenectomized

150

59.1

112/248

45.2

Children (<18 y)

Adults (≥ 18 y)

Gallstones

n*

% or median (range)

n

% or median (range)

86

18 (1-312)

63

39 (1-516)

Missense/missense

55/97

57

55/94

58

Missense/nonmissense

26/97

27

25/94

27

Nonmissense/nonmissense

16/97

16

14/94

15

11.3 (7.6-14.2)

Lifetime transfusions, n
Genotype†

Hemoglobin (g/dL)
Nonsplenectomized NRT

40

9.1 (6.0-12.5)

30

Splenectomized NRT

24

8.5 (4.3-12.8)

52

8.5 (6.1-12.3)

40

0.30 (0.07-5.36)

42

0.21 (0.09-6.52)

Reticulocytes, %

87

11.2 (0.4-82.9)

54

18.9 (2.5-76)

Bilirubin, mg/dL

80

3.6 (0.1-33.1)

78

4.1 (0.9-17.6)

Absolute reticulocyte count (3106 cells/mL)

Lactate dehydrogenase, U/L

46

775 (183-3811)

66

220 (127-1007)

Ferritin, ng/mL

63

917 (22-13409)

72

594 (32-8220)

NRT, not regularly transfused with ,6 transfusions per year.
*Sample sizes are those with known data for the given characteristic in the PKD NHS.
†Those from the Amish community (homozygous R479H mutation) were excluded.5

parents at enrollment, by 72 parents at the 1-year follow-up, and by 59
parents at the 2-year follow-up. The median child self-report score was
82.6 (range, 33.7-100), and the median parent proxy score was 83.5
(range, 25-100). The median child self-report and parent proxy scores
were unchanged at 1 and 2 years of follow-up.

children were excluded from the analysis, signiﬁcantly lower HRQoL
was reported in children who were splenectomized (76 vs 83; P 5
.02) and in those receiving a higher number of lifetime transfusions
(77 vs 82; P 5 .02); however, there was no longer a signiﬁcant difference in HRQoL by hemoglobin level (P 5 .23).

The report of HRQoL in children did not differ by age group (ages 2-4,
5-7, and 8-12 years vs 13-17 years; P 5 .34) or by sex (P 5 .69).
Amish children reported higher HRQoL scores (93 vs 80; P 5
.007). HRQoL was signiﬁcantly lower in children who were more anemic (,8 g/dL vs .8 g/dL, 69 vs 91; P 5 .01), had iron overload by
ferritin (34 vs 92; P 5 .006), or had iron overload by chelation requirement (70 vs 88; P 5 .007). HRQoL scores also signiﬁcantly differed
by PKLR genotype, with those with a nonmissense/nonmissense
genotype reporting a signiﬁcantly lower HRQoL (missense/missense
vs missense/nonmissense vs nonmissense/nonmissense, 83 vs 84 vs
59; P 5 .006). HRQoL did not differ based on splenectomy status
(P 5 .64), bilirubin level (total bilirubin . 4 mg/dL vs ,4 mg/dL;
P 5 .69), receipt of regular transfusions vs not (P 5 .21), total number
of lifetime transfusions (P 5 .06), iron status by ferritin (P 5 .12), or
history of extramedullary hematopoiesis (P 5 .07). When Amish

Report of fatigue in children with PKD

22 MARCH 2022 • VOLUME 6, NUMBER 6

Peds-FACIT-F. Peds-FACIT-F was completed by 47 older children
and adolescents at enrollment and by 40 and 36 older children and
adolescents at 1 and 2 years, respectively. The median score at enrollment was 45 (range, 16-52), and it was unchanged at 1 and 2 years of
follow-up. There was no difference in the report of fatigue by age
group (P 5 .17), sex (P 5 .46), splenectomy status (P 5 .76), number
of lifetime transfusions (P 5 .14), current transfusion status (P 5 .09),
hemoglobin level (P 5 .41), bilirubin level (P 5 .54), or iron overload
by ferritin (P 5 .83) in this cohort at enrollment. Amish children
reported fatigue that was similar to that of non-Amish children
(median, 46 vs 45, respectively; P 5 .14). The report of fatigue varied
signiﬁcantly by PKLR genotype, with those with a nonmissense/nonmissense genotype reporting higher levels of fatigue (missense/
QUALITY OF LIFE AND FATIGUE IN PKD
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Overall
,18 y old

Table 2. HRQoL survey results by age group at enrollment
Surveys

n (%)

Median (range)

EQ-5D Visual Analog Scale (range 0 [worst] to
100 [best])

120 (92)

80 (20-100)

EQ-5D Health Index Score* (range 0 [worst] to 1
[best])

86 (66)

0.88 (0.43-1)

FACT-An (range 0 [most fatigue] to 188)

126 (96)

156 (33-181)

PROMIS SF-7a (mean, 50; SD, 10; higher is
worse)

60 (46)

52.3 (29.4-80.3)†

Adult surveys (n = 131)

Pediatric surveys (n = 123)

Parent proxy

86 (70.0)

83.5 (25-100)

Child self-report

61 (49.6)

82.6 (33.7-100)

50 (40.7)

70.4 (31-80)

Peds-FACIT-F (range 0 [most fatigue] to 52)
PROMIS Fatigue Child SF-10a (mean, 50; SD,
10; higher is worse)
Child self-report 10a

36 (29.3)

41.6 (30.3-65.7)

Parent proxy report 10a

48 (39.0)

46.3 (34.1-69.2)

*EQ-5D Health Index Score could only be analyzed for participants from the United
States, Germany, and The Netherlands.
†Median T score (range).

missense vs missense/nonmissense vs nonmissense/nonmissense,
46 vs 45 vs 34; P 5 .047). Children with a history of chelation therapy
also reported higher levels of fatigue (median, 40 vs 46; P 5 .03). Differences, or the lack thereof, in Peds-FACIT-F scores in certain subgroups are shown in Figure 2.

PROMIS Child SF-10a. The PROMIS Child SF-10a was completed by 36 older children and adolescents with a median score of
41.6 (range, 30.3-65.7). The PROMIS Parent Proxy was completed
by 48 parents with a median score of 46.3 (range, 34.1-69.2). The
median child self-report and parent proxy reports were unchanged
at follow-up. There was no signiﬁcant difference in the report of fatigue
by age (P 5 .31), sex (P 5 .82), splenectomy status (P 5 .88), number of lifetime transfusions (P 5 .07), transfusion status (P 5 .06),
hemoglobin level (P 5 .18), bilirubin level (P 5 .94), iron overload
by ferritin (P 5 .12), or iron overload by chelation requirement (P 5
.19). There also was no signiﬁcant difference in the report of fatigue
by PKLR genotype (median scores for missense/missense vs missense/nonmissense vs nonmissense/nonmissense, 42 vs 44 vs 56;
P 5 .08). Although there was no difference in the report of fatigue
between Amish and non-Amish children, as measured by PROMIS,
when Amish children were excluded from the analysis, a signiﬁcantly
higher level of fatigue was reported in children with a history of iron
overload by ferritin (57 vs 32; P 5 .008) and by chelation requirement
(57 vs 41; P 5 .009).
Other report of symptoms of anemia. English-speaking
children were asked additional questions generated for symptom
assessment speciﬁc to PKD (Table 3). Of the 40 children who completed the questionnaire, 35% (14/40) reported that their jaundice
upset them at least some of the time; 7.5% (3/40) reported that
they felt upset most or all of the time.
1848
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This is the ﬁrst report of HRQoL and fatigue in patients with PKD using
validated instruments. A wide range of scores was reported for general HRQoL, as measured by the EQ-5D in adults and the PedsQL
4.0 in children, and for fatigue using FACIT-F in adults, Peds-FACITF in children, and PROMIS in all ages. Consistent correlates were
identiﬁed between speciﬁc clinical characteristics in patients with
PKD and worse overall HRQoL and fatigue (Table 4).
The median reported general HRQoL, as measured by EQ-5D in
adults and PedsQL 4.0 in children, approximated that of the general
population. There are numerous possible explanations for this ﬁnding.
There is a very wide range of disease spectrum in the analyzed cohort,
from asymptomatic individuals with no anemia to individuals who were
transfusion dependent since birth.15 Consistent with the large variation in symptoms and complications, some patients reported very
low HRQoL or a high level of fatigue, whereas others reported the
best possible HRQoL or no fatigue. In addition, adjustment to chronic
anemia and a lack of recognition of its impact on functional status are
well described in populations with congenital anemia; this may also be
responsible for the observed ﬁndings. Another possibility lies with the
selected instruments, which, although validated tools, are not validated for use in PKD, hemolytic anemias, or congenital anemias.
Therefore, they may be more sensitive to acquired anemia, such as
the anemia associated with chronic kidney disease or cancer. The
instruments may be insensitive to aspects of lifelong hemolytic anemia
that reduce HRQoL, including iron overload, chronic jaundice, and
pulmonary hypertension. Finally, there may be speciﬁc aspects of
PKD that modulate the impact of chronic anemia, such as the elevation in 2,3-diphosphoglycerate (2,3-DPG).16,17 2,3-DPG is an important regulator of the oxygen afﬁnity of hemoglobin and is increased in
PKD as a result of the metabolic block of glycolysis resulting in an
upstream accumulation of glycolytic intermediates. Therefore,
enhanced oxygen delivery due to elevated 2,3-DPG may obviate
symptoms of anemia in some patients.6,18
Although these factors may limit the ability to compare the results of
these instruments with other patient populations, comparisons within
the population of patients with PKD are informative. Among adults,
worse HRQoL and fatigue were consistently reported in patients
receiving regular transfusions, those with pulmonary hypertension,
and females. In FACT-An subscales, receipt of regular transfusions
was associated with signiﬁcantly lower physical, emotional, and social
well-being, as well as with increased symptoms of anemia. Worse
HRQoL and fatigue were also generally associated with iron overload
in children and adults. Although iron chelation is associated with
potential side effects, laboratory monitoring, and costs, this ﬁnding
may also be a marker of transfusion status. Although symptoms within
a patient are typically experienced at a certain hemoglobin level, this
level may vary among patients. Therefore, transfusions are not typically
initiated based on a speciﬁc hemoglobin level across the population,
but rather to improve a given individual’s fatigue and HRQoL based on
their reported symptoms. However, patients who start regular transfusions may be more symptomatic, and transfusions may not signiﬁcantly improve HRQoL given the burden of time, energy, and cost
placed on the patient to undergo the intervention; this emphasizes
the need for effective new therapies in this disease. The same overall
principle (ie, that more symptomatic patients are more likely to
undergo splenectomy) may explain the ﬁnding that splenectomy
was associated with greater fatigue in adults and worse HRQoL in
22 MARCH 2022 • VOLUME 6, NUMBER 6
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Figure 1. HRQoL as assessed by FACT-An in adults with PKD, by speciﬁc relevant subgroupings. Median hemoglobin (A), transfusion status (B), iron overload status
(C), splenectomy status (D), and genotype (E). Higher FACT-An scores indicate higher HRQoL. The R479H/R479H genotype is primarily found in the Amish community. M/M,
missense/missense; M/NM, missense/nonmissense; NM/NM, nonmissense/nonmissense.

children, despite the fact that this is a 1-time procedure that is performed to improve hemoglobin levels and reduce transfusion needs.
Pulmonary hypertension is a serious and relatively rare complication of
PKD affecting 3% of individuals.5 Patients with this complication
reported substantially reduced HRQoL and signiﬁcantly increased
fatigue. Physical and functional well-being were particularly impacted.
Therefore, consideration of the possibility of pulmonary hypertension
is critical in patients with concerning symptoms and demands aggressive management when identiﬁed.
Children, but not adults, reported signiﬁcantly lower HRQoL with severe
anemia (deﬁned as a hemoglobin level , 8 g/dL). In the general PKD
22 MARCH 2022 • VOLUME 6, NUMBER 6

population, the relationship between hemoglobin and symptoms is not
consistent between patients; however, in individual patients, there is
often a relationship between hemoglobin level and symptoms, including
fatigue.6,15 Future studies with paired measurement of HRQoL, in
patients before and after therapy to increase their hemoglobin, will help
to explore the relationship between hemoglobin and symptoms and capture the impact that improving the hemoglobin level has on HRQoL.
Additional differences in the clinical characteristics associated with
reduced HRQoL and fatigue between children and adults included
age, sex, and genotype. Older age was associated with reduced
HRQoL in adults but not children. Reduced HRQoL with advancing
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Table 3. Additional symptom assessment in children and adults with PKD
Age ≥ 18 y

Total, n

I get upset about my jaundice (yellow eyes/skin)

Not at all

68

Age < 18 y

A little bit

Somewhat

Quite a bit

Very much

28 (41.2)

18 (26.4)

11 (16.2)

5 (7.4)

6 (8.8)

None of the time

A little of the time

Some of the time

Most of the time

All of the time

I get upset about my jaundice (yellow eyes/skin)

40

26 (65)

7 (17.5)

4 (10)

1 (2.5)

2 (5)

I have trouble walking

40

34 (85)

2 (5)

2 (5)

2 (5)

0

I feel lightheaded (dizzy)

41

26 (63.4)

8 (19.5)

7 (17.1)

0

0

I have been short of breath

40

24 (60)

8 (20)

7 (17.5)

1 (2.5)

0

I have pain in my chest

40

32 (80)

5 (12.5)

3 (7.5)

0

0

I am less motivated to do my usual activities

40

26 (65)

7 (17.5)

7 (17.5)

0

0

disease, the population was heterogeneous. The follow-up period
was just 2 years and assessed patients at 3 time points. The instruments are generic, and cancer-speciﬁc measures of HRQoL and
fatigue are likely insensitive to many of the unique aspects of PKD
and congenital hemolytic anemias more generally.24 In this study, participants noted a signiﬁcant impact of jaundice on HRQoL in a
disease-speciﬁc assessment. This is notably absent from the validated
anemia questionnaires but represents an important symptom that
future therapies should aim to improve. In patients with a congenital
anemia, it may be difﬁcult to assess fatigue or HRQoL except in the
setting of a therapeutic intervention, such as pre/postsplenectomy,
pre/posttransfusion, or pre/post a novel therapeutic. HRQoL instruments speciﬁc to the symptoms and impact of PKD have recently
been developed25 and are being validated in phase 3 clinical trials
of a novel therapy. If these new instruments perform well, they may
be optimal for future studies evaluating HRQoL in PKD.

age is not unexpected in general, especially in the population with
PKD, because symptoms of the disease may become more pronounced with age-related declines in cardiopulmonary function,
increasing comorbidities, and emergence of time-dependent complications, such as bone disease and iron overload.6 In addition, female
sex was associated with reduced HRQoL and greater fatigue in adults
but not in children. Reduced HRQoL in adult females of a given population compared with male counterparts has been reported in a number of other chronic conditions19 and is not well understood. This may
be related to gender-based differences in reporting,20,21 higher rates
of anxiety and depression in women22 that may result in lower HRQoL,
or an inherent fault in the design of the instruments themselves, among
other possibilities.
The presence of 2 severe mutations (nonmissense/nonmissense) is
associated with worse anemia, more transfusion requirements, and
more complications overall5,23; therefore, it is expected that this would
result in reduced HRQoL and increased fatigue. It is not clear why this
correlation between genotype and HRQoL and fatigue was seen in
children, but not in adults, because the increased severity imparted
by genotype persists throughout life.

In conclusion, this ﬁrst report of HRQoL and fatigue measurement in a
large cohort of patients with PKD using validated standardized instruments found similar HRQoL for patients with PKD and the general population but higher levels of fatigue. Female sex, receipt of regular
transfusions, iron overload, and pulmonary hypertension were consistently associated with worse health-related outcomes in adults, whereas

Although our study has a number of notable strengths, it also has several limitations. Although the sample size was large for this rare

Table 4. Patient characteristics signiﬁcantly associated with reduced HRQoL or greater fatigue by HRQoL or fatigue instrument in adults

and children
Adults
Characteristic

EQ-5D

Children

FACT-An

PROMIS SF-7a

X

PedsQL 4.0

Peds-FACIT-F

X

Older age

X

Female sex

X

X

Non-Amish

X

X

X

X

A

Splenectomized
Regularly transfused

X

X

Iron overload: any chelation use

X

X

X

Iron overload: ferritin . 1000 ng/mL
Pulmonary hypertension

X

X

X

A

X

A

X

Nonmissense/nonmissense genotype

X

Hemoglobin , 8 g/dL

X

$18 total transfusions

A

X

A, signiﬁcant only when the Amish population was excluded from analysis; X, signiﬁcant in entire cohort.
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Data are n (%) unless otherwise speciﬁed.

A

B
50

Peds-FACIT-F score

Peds-FACIT-F score

50

40

30

40

30

20

20
<8.0

>8.0

No

C

Yes

Regularly transfused

D
50

Peds-FACIT-F score

Peds-FACIT-F score

50

40

30

40

30

20

20
No

No

Yes

Iron overload

Yes

Splenectomized

E
Peds-FACIT-F score

50

40

30

20
M/M

M/NM

NM/NM

Genotype
Figure 2. Fatigue as assessed by Peds-FACIT-F in children with PKD, by speciﬁc relevant subgroupings. Including median hemoglobin (A), transfusion status (B), iron
overload status (C), splenectomy status (D), and genotype (E). Higher Peds-FACIT-F scores indicate less fatigue. M/M, missense/missense; M/NM, missense/nonmissense; NM/
NM, nonmissense/nonmissense.

more severe anemia, iron overload, and 2 nonmissense PKLR mutations were associated with worse patient-reported outcomes in children. Based on the ﬁndings of this study, future studies of HRQoL in
patients with PKD should use disease-speciﬁc instruments and evaluate the impact of therapeutic interventions on these outcomes.
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